Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,791,140

« Back to Dashboard
Patent 8,791,140 protects INLYTA and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.

Summary for Patent: 8,791,140

Title:Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Inventor(s): Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/594,575
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
TABLET;ORAL202324-001Jan 27, 2012RXNo8,791,140Aug 5, 2030Y
Pf Prism Cv
TABLET;ORAL202324-002Jan 27, 2012RXYes8,791,140Aug 5, 2030Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,791,140

PCT Information
PCT FiledMarch 25, 2008PCT Application Number:PCT/IB2008/000792
PCT Publication Date:October 16, 2008PCT Publication Number: WO2008/122858

International Patent Family for Patent: 8,791,140

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2014193900<disabled in preview>
South Korea20090127949<disabled in preview>
South Korea101237588<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.